Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (63 page)

• Treatment: treat underlying disease ± iron and/or erythropoiesis-stimulating agent (ESA, eg, Epo). Iron if ferritin <100 or Fe/TIBC <20%. Consider ESA if Epo <500. Avoid ESA in cancer if treatment goal is cure (
Leuk Res
2012;36:939). Unclear if one should treat highly sx Pts w/ goal Hb 10–12 g/dL; weigh risk of thrombosis.

Anemias of chronic disorders

• Anemia of chronic inflammation (see above) • Anemia of chronic kidney disease: ↓ Epo; treat w/ Epo (see “Chronic Kidney Disease”) • Endocrine deficiencies: hypometabolism and ↓ O
2
demand with thyroid, pituitary, adrenal, or parathyroid disease → ↓ Epo; can be normocytic or macrocytic
Sideroblastic anemia
(see above)
Pure red cell aplasia
• Destructive antibodies or lymphocytes → ineffective erythropoiesis • Associated with thymoma, CLL and parvovirus infection • Diagnostic studies:
lack of erythroid precursors on BM bx
, other lines normal • Treatment: thymectomy if thymus enlarged; IVIg if parvovirus infection; immunosuppression if CLL or idiopathic; supportive care with PRBC transfusions; ? erythropoietin receptor agonist if due to antierythropoietin Ab (
NEJM
2009;361:1848)

MACROCYTIC ANEMIAS

includes megaloblastic and nonmegaloblastic causes
Megaloblastic anemia


Impaired DNA synthesis
→ cytoplasm matures faster than nucleus → ineffective erythropoiesis and macrocytosis; due to
folate
or
B12 deficiency
;
MDS
• ✓
folate
and
vitamin B12
; ↑ LDH & indirect bilirubin (due to ineffective erythropoiesis) • Smear:
neutrophil hypersegmentation
,
macro-ovalocytes
, anisocytosis, poikilocytosis
Folate deficiency
• Folate present in leafy green vegetables and fruit; total body stores sufficient for
2–3 mo
• Etiologies:
malnutrition
(alcoholics, anorectics, elderly), ↓ absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim), ↑ requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis) • Diagnosis: ↓ folate; ↓ RBC folate, ↑ homocyst. but nl methylmalonic acid (unlike B
12
defic.) • Treatment: folate 1–5 mg PO qd for 1–4 mo or until complete hematologic recovery;
critical to r
/
o B
1
2
deficiency first (see below)
Vitamin B
12
deficiency
(
NEJM
2013;368:149)
• B
12
present only in foods of animal origin; total body stores sufficient for
2–3 y
• Binds to
intrinsic factor
(IF) secreted by gastric parietal cells; absorbed in terminal ileum • Etiologies: malnutrition (alcoholics, vegans),
pernicious anemia
(PA, autoimmune disease against gastric parietal cells, a/w polyglandular endocrine insufficiency and ↑ risk of gastric carcinoma), other causes of ↓ absorption (gastrectomy, sprue, Crohn’s disease), ↑ competition (intestinal bacterial overgrowth, fish tapeworm) • Clinical manifestations:
neurologic
changes (
subacute combined degeneration
) affecting peripheral nerves, posterior and lateral columns of the spinal cord and cortex → numbness, paresthesias, ↓ vibratory and positional sense, ataxia, dementia • Dx: ↓ B
12
; ↑ homocysteine and methylmalonic acid; anti-IF Ab; Schilling test; ↑ gastrin in PA • Treatment: 1 mg B
12
IM qd × 7 d → q wk × 4–8 wk → q month for life neurologic abnormalities are reversible if treated w/in 6 mo folate can reverse
hematologic
abnormalities of B
12
deficiency but not
neurologic
changes (and can lead to “steal” of B
12
stores → worsening of neuro complications) oral supplementation (2 mg qd) appears feasible as well (
Blood
1998;92:1191) even w/o IF

Nonmegaloblastic macrocytic anemias


Liver disease
: often macrocytic, may see target cells •
Alcoholism
: BM suppression & macrocytosis independent of folate/B
12
defic. or cirrhosis •
Reticulocytosis

Other causes
: hypothyroidism; MDS; meds that impair DNA synthesis (zidovudine, 5-FU, hydroxyurea, Ara-C); hereditary orotic aciduria; Lesch-Nyhan syndrome.

PANCYTOPENIA

Etiologies

• Hypocellular bone marrow (nl cellularity ~100 – age):
aplastic anemia
, hypoplastic MDS
• Cellular bone marrow:
MDS
, aleukemic leukemia, PNH, severe megaloblastic anemia • Marrow replacement (myelophthisis):
myelofibrosis
, metastatic solid tumors, granulomas • Systemic diseases: hypersplenism, sepsis, alcohol, toxins
Clinical manifestations
• Anemia → fatigue • Neutropenia → recurrent infections • Thrombocytopenia → mucosal bleeding & easy bruisability
Aplastic anemia
= stem cell failure (
Lancet
2005;365:1647;
Blood
2012;120:1185)
• Epidemiology: 2–5 cases/10
6
/y; biphasic (major peak in adolescents, 2nd peak in elderly) • Diagnosis: pancytopenia w/ ↓ retics, BM bx w/ cytogenetics showing hypocellularity • Etiologies:
idiopathic
(
1
/
2

1
/
3
of cases)
stem cell destruction
:
radiation
,
chemotherapy
,
chemicals
(eg, benzene) idiosyncratic
med rxn
(eg, chloramphenicol, NSAIDs, sulfa drugs, gold, carbamazepine, antithyroid)
viruses
(HHV-6, HIV, EBV, parvovirus B19); also
post-hepatitis
(non A, B or C)
immune disorders
(SLE, GVHD post-HSCT, thymoma)
PNH (see below); Fanconi’s anemia (congenital disorder w/ pancytopenia, macrocytic anemia, ↑ risk of MDS, AML, & SCC of head & neck, and multiple physical anomalies);
shortened telomeres: seen w/ telomerase (
TERT, TERC
) mut (10% of aplastic anemia), dyskeratosis congenita/DKC1 mut; a/w IPF, cirrhosis (
NEJM
2009;361:2353)
• Treatment and prognosis
allogeneic HSCT
: for
young
Pts → ~80% long-term survival and significantly ↓ risk of malignant evolution, but has risk of transplant-related morbidity & mortality; if possible avoid transfusions (and alloimmunization) pretransplant
immunosuppression
(CsA/tacrolimus,  ATG): 70–80% respond, with 80–90% 5-y survival in responders (96% vs. 76% w/ horse vs. rabbit ATG;
NEJM
2011;365:430); 15–20% 10-y incidence of clonal disorders (mostly MDS,  AML, PNH)
TPO mimetics
(eg, eltrombopag) may be option in refractory disease (
NEJM
2012;367:11)
supportive care:
transfusions, antibiotics, possible utility of G-CSF and Epo

Myelodysplastic syndromes (MDS)
(qv)
Paroxysmal nocturnal hemoglobinuria (PNH)
(
Blood
2009;113:6522)
• Acquired clonal stem cell disorder = inactivating somatic mutation of
PIG-A
gene → deficiency of GPI-anchor for CD55 & CD59 (inhib of complement) → complement-mediated RBC lysis, plt aggreg., & hypercoagulability • Clinical: intravascular
hemolytic anemia
,
hypercoagulability
(venous > arterial; esp. intraabdominal, cerebral), smooth muscle dystonias,
deficient hematopoiesis
(cytopenias); a/w aplastic anemia, MDS and evolution to AML

• Dx:
flow cytometry
(↓ CD55 & CD59) on RBCs and granulocytes; urine hemosiderosis • Treatment: supportive care (iron, folate, transfusions); consider anti-coagulation allogeneic HSCT for hypoplasia or severe thrombosis eculizumab (Ab inactivates terminal complement C5s): ↓ hemolysis, improves QoL & stabilizes Hb levels (
NEJM
2004;350:552 & 2006;355:1233;
Lancet
2009;373:759); must have meningococcal vaccination
Myelophthisic anemia
(see also “Primary Myelofibrosis”)
• Infiltration of bone marrow by cancer, leukemia, infection, fibrosis (primary myelofibrosis), granulomas, lysosomal storage disorders

HEMOLYTIC ANEMIAS

Diagnostic evaluation

• ↑ reticulocyte count (RI >2%), ↑ LDH, ↓ haptoglobin (83% Se, 96% Sp), ↑ indirect bili • Autoimmune hemolysis: Coombs’ test = direct antiglobulin test (DAT) →
if agglutination occurs when antisera against Ig or C3 are applied to patient RBCs • Intravascular: ↑↑ LDH, ↓↓ haptoglobin; hemoglobinemia, hemoglobinuria, hemosiderinuria • Extravascular: splenomegaly • Family h/o anemia; personal or family h/o cholelithiasis
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
(
Lancet
2008;371:64)
• X-linked defect of metabolism (
G6PD
mutations) w/ ↑ susceptibility to oxidative damage • Most common in
of African or Mediterranean descent (malaria-endemic areas) • Hemolysis precipitated by
drugs
(sulfonamides, dapsone, primaquine, doxorubicin, methylene blue),
infection
,
DKA
or
foods
(fava beans in children) • Diagnosis: smear may show RBC
Heinz bodies
(oxidized Hb) that result in
bite cells
once removed by spleen; ↓ G6PD levels (
may be normal after acute hemolysis
as older RBCs have already lysed and young RBCs may still have near normal levels)
Sickle cell anemia
(
Lancet
2010;376:2018)
• Recessive β-globin mutation → structurally abnl hemoglobin (HbS). ~8% African Americans heterozygotes (“sickle trait”; usually w/o sx); ~1/400 homozygotes (sickle cell disease).

Other books

Dream of the Blue Room by Michelle Richmond
The Silver Lake by Fiona Patton
Country Brides by Debbie Macomber
The Hollow by Nora Roberts
The End of Diabetes by Joel Fuhrman
The Judas Rose by Suzette Haden Elgin
Influx by Kynan Waterford